Whitepaper: Regulatory Aspects of Psychedelic Drugs

Unlock the potential of psychedelic drugs with our in-depth whitepaper, “Regulatory Aspects of Psychedelic Drugs.” This comprehensive document explores the evolving regulatory landscape, tracing the historical context of psychedelics, analysing current frameworks, and examining emerging trends and future directions.

This whitepaper serves as a valuable resource for researchers, drug developers, healthcare professionals, and industry stakeholders, offering a roadmap to navigate the future of psychedelic drug regulation.

Whitepaper - Regulatory Aspects of Psychedelic Drugs - Current & Future Outlook

Meet Our Experts

Roy Pengilley

Senior Regulatory Consultant, Orphix Consulting GmbH, DLRC Group

Roy is a global regulatory professional with pharmaceutical development experience across a wide range of pharmaceutical presentations and therapeutic areas. He has strong scientific, regulatory, and managerial expertise in driving both early development projects (IMPD) and full development programs (MAA). Roy has a proven ability to lead a team through complex global regulatory submissions including interactions with several global health authorities.

Contact Roy

Anuya Aras

Senior Regulatory Executive, Orphix Consulting GmbH, DLRC Group

Anuya is a Senior Regulatory Affairs Executive who holds a broad experience in the Pharmaceutical industry and 3 years in Regulatory Affairs. She has strong experience including CMC Regulatory, pharmaceutical and chemical development, product development strategy, scientific advice, PIPs, ODDs, CUPs, Regulatory Operations and Submissions.

Contact Anuya

Contact our experts Explore our services Follow us on LinkedIn